- Home
- CFSB vs IFRX Comparison
CFSB vs IFRX Comparison
Compare CFSB & IFRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CFSB
- IFRX
- Stock Information
- Founded
- CFSB 1889
- IFRX 2007
- Country
- CFSB United States
- IFRX Germany
- Employees
- CFSB N/A
- IFRX N/A
- Industry
- CFSB Major Banks
- IFRX Biotechnology: Pharmaceutical Preparations
- Sector
- CFSB Finance
- IFRX Health Care
- Exchange
- CFSB Nasdaq
- IFRX Nasdaq
- Market Cap
- CFSB 51.6M
- IFRX 53.5M
- IPO Year
- CFSB N/A
- IFRX 2017
- Fundamental
- Price
- CFSB $13.80
- IFRX $0.90
- Analyst Decision
- CFSB
- IFRX Strong Buy
- Analyst Count
- CFSB 0
- IFRX 4
- Target Price
- CFSB N/A
- IFRX $7.75
- AVG Volume (30 Days)
- CFSB 4.0K
- IFRX 356.2K
- Earning Date
- CFSB 08-05-2025
- IFRX 08-07-2025
- Dividend Yield
- CFSB N/A
- IFRX N/A
- EPS Growth
- CFSB N/A
- IFRX N/A
- EPS
- CFSB N/A
- IFRX N/A
- Revenue
- CFSB $7,484,000.00
- IFRX $140,242.00
- Revenue This Year
- CFSB N/A
- IFRX N/A
- Revenue Next Year
- CFSB N/A
- IFRX $1,276.37
- P/E Ratio
- CFSB N/A
- IFRX N/A
- Revenue Growth
- CFSB N/A
- IFRX 30.90
- 52 Week Low
- CFSB $6.34
- IFRX $0.71
- 52 Week High
- CFSB $13.88
- IFRX $2.82
- Technical
- Relative Strength Index (RSI)
- CFSB 76.31
- IFRX 52.02
- Support Level
- CFSB $13.84
- IFRX $0.82
- Resistance Level
- CFSB $13.88
- IFRX $0.89
- Average True Range (ATR)
- CFSB 0.00
- IFRX 0.06
- MACD
- CFSB -0.08
- IFRX 0.01
- Stochastic Oscillator
- CFSB 11.76
- IFRX 75.92
About CFSB CFSB Bancorp Inc.
CFSB Bancorp Inc provides banking services. It offers a variety of financial services to individuals and small businesses through its offices in Quincy, Holbrook, and Weymouth. Its primary deposit products are savings, checking, and term certificate accounts, and its primary lending product is residential mortgage loans.The Company's loan portfolio includes residential real estate, commercial real estate, construction, and consumer loan segments. Residential real estate loans include classes for one- to four-family, multi-family, second mortgages and home equity lines of credit.
About IFRX InflaRx N.V.
InflaRx NV is a clinical-stage biopharmaceutical company focused on applying proprietary anti-C5a/C5aR technology to discover and develop first-in-class, potent, and specific inhibitors of the complement activation factor known as C5a and its receptor known as C5aR. C5a is an inflammatory mediator involved in the progression of a wide variety of autoimmune and other inflammatory diseases. Its product candidate, vilobelimab, is a novel intravenously delivered first-in-class anti-C5a monoclonal antibody that selectively binds to free C5a and has demonstrated disease-modifying clinical activity and tolerability in multiple clinical settings.